SHANGHAI, China, Sept. 19 China-Biotics,Inc. (OTC Bulletin Board: CHBT) (''China-Biotics," "the Company"), a leadingChinese firm specializing in the manufacture, research, development, marketingand distribution of probiotics products, announced today that at its 2008Annual General Meeting of Shareholders (the ''AGM''), stockholders re-electedall of the Company's nominees to the Board of Directors.
At the meeting, held September 12, 2008, shareholders approved there-election of Mr. Jinan Song, Dr. Ji Wei Chin, Dr. Wen Min Du and Mr. SimonYick as members of the Company's Board of Directors. Shareholders alsoratified the appointment of BDO McCabe Lo Limited as the Company's independentauditors for the fiscal year ending March 31, 2008.
About China-Biotics, Inc.
China-Biotics, Inc. ("China-Biotics," "the Company''), a leadingmanufacturer of biotechnology products and supplements, engages in theresearch, development, marketing and distribution of probiotics dietarysupplements. Through its wholly owned subsidiary, Shanghai ShiningBiotechnology Co., Ltd., the Company has operations in Shanghai. Itsproprietary product portfolio contains live microbial nutritional supplementsunder the ''Shining'' brand. Currently, the products are sold OTC throughlarge distributors to pharmacies and supermarkets in Shanghai, Jiangsu, andZhejiang. China-Biotics plans to launch 300 Shining brand retail outlets inmajor cities in China. Currently, China-Biotics is strategically expandingits production capacity of probiotics to meet growing demand in the bulkadditive market. For more information, please visithttp://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Any statements set forth above that are not historical facts areforward-looking statements that involve risks and uncertainties that couldcause actual results to differ materially from those in the forward-lookingstatements. Such factors include, but are not limited to, the Company'sability to market existing and new products, ability to access to capital forexpansion, and changes from anticipated levels of sales, future national orregional economic and competitive conditions, changes in relationships withcustomers, dependence on its flagship product profits and other factorsdetailed from time to time in the Company's filings with the United StatesSecurities and Exchange Commission and other regulatory authorities. TheCompany undertakes no obligation to publicly update or revise anyforward-looking statements, whether as a result of new information, futureevents or otherwise.For more information, please contact: CCG Investor Relations Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: firstname.lastname@example.org Web: http://www.ccgirasia.com
SOURCE China-Biotics, Inc.